Retinoblastoma Treatment Market Set to Touch US$ 3.0 Billion by 2030, According to RationalStat Analysis

[New Report on Global Retinoblastoma Treatment Market 2023] – The global retinoblastoma treatment market is expected to reach US$ 3.0 billion by 2030, with an annual growth rate of 4.5%


Wilmington, Delaware, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Global Retinoblastoma Treatment Market value is US$ 2.2 billion in 2023 and is predicted to rise at a substantial CAGR of 4.5% during the forecast period of 2023 and 2030 according to RationalStat analysis.


Market Definition, Market Scope, and Report Overview

Retinoblastoma is an uncommon form of eye cancer that arises in the retina, the light-sensitive tissue at the back of the eye. It most commonly affects children under the age of five, but it can also affect older children and adults. The goal of retinoblastoma treatment is to remove the cancer while saving the eye. The treatment choices available are determined by the size and location of the malignancy, as well as the age and overall health of the child.

  • According to a deep-dive market assessment by RationalStat, the global Retinoblastoma Treatment market has been analyzed on the basis of market segments, including treatment type, type of retinoblastoma, type of staging and geography/regions (including North America, Latin America, Western Europe, Eastern Europe, Middle East & Africa, and Asia Pacific). The report also offers global and regional market sizing for the historical period of 2019-2022 and the forecast period of 2023-2030.
  • Market intelligence for the global Retinoblastoma Treatment market covers market sizes on the basis of market value (US$/EUR Million) and volume (Units/Number of Patients) by various products/services/equipment, demand assessment across the key regions, customer sentiments, price points, cost structures, margin analysis across the value chain, financial assessments, historical and forecast data, key developments across the industry, import-export data, trade overview, components market by leading companies, etc.
  • In addition, the long-term sector and products/services 10-year outlook and its implications on the global Retinoblastoma Treatment market. It also includes the industry's current state – Production Levels, Capacity Utilization, Tech quotient, etc. Key information will be manufacturing capacity by country, installed base, import volumes, market size, key players, market size, dynamics, market data, insights, etc.

Request A Customization- https://store.rationalstat.com/store/global-retinoblastoma-treatment-market/#tab-ux_global_tab

Global Retinoblastoma Treatment Market: Segmental and Market Share Analysis

  • On the basis of type of retinoblastoma, non-hereditary retinoblastoma is expected to hold a significant market share over the forecast period due to increasing number of cases of no-hereditary retinoblastoma.
  • On the basis of region, North America has a sizable market share for retinoblastoma therapy and is likely to maintain its dominance during the forecast period. This region's market share is likely to grow in the future.

Report Synopsis

Report Metrics Details
Base Year 2023
Forecast Period 2023-2030
Base Year Market Size US$ 2.2 billion
Market Size Forecast US$ 3.0 billion
Growth Rate 4.5%
Key Market Drivers
  • Advancements in medical technology
  • Ongoing research and development
  • Increasing incidence rates
  • Improved healthcare infrastructure
Companies Profiled
  • Baxter International Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cellceutix Corporation
  • Icon Bioscience
  • RXi Pharmaceuticals

Explore more about this report- https://store.rationalstat.com/store/global-retinoblastoma-treatment-market/#tab-ux_global_tab

Competition Analysis and Market Structure

Prominent companies and leading players adopt various strategies in order to reinforce their market share and gain a competitive edge over other competitors in the market. Mergers & acquisitions, partnerships and collaborations, and product launches are some of the strategies followed by industry players. Some of the key developments in the global retinoblastoma treatment market include,

  • In September 2022, Researchers from the University of Texas Southwestern Medical Centre and the University of Miami discovered an estrogen-related receptor gamma, or ESRRG, that is overactive and increases tumour cell survival in retinoblastoma. The scientists reported in Science Advances that blocking ESRRG kills retinoblastoma cells.

Some of the prominent players and suppliers operating and contributing significantly to the global retinoblastoma treatment market growth include Baxter International Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cellceutix Corporation, Icon Bioscience, and RXi Pharmaceuticals, among others.

Get A Free Sample- https://store.rationalstat.com/store/global-retinoblastoma-treatment-market/#tab-ux_global_tab

RationalStat has segmented the global retinoblastoma treatment market based on treatment type, type of retinoblastoma, type of staging, and region

  • Global Retinoblastoma Treatment Market Value (US$ Million), Volume (Units/Number of Patients), and Market Share (2019-2030) Analysis by Treatment Type
    • Surgery
    • Chemotherapy
    • Radiation Therapy
    • Laser Therapy
    • Cryotherapy
    • Bone Marrow Transplantation
  • Global Retinoblastoma Treatment Market Value (US$ Million), Volume (Units/Number of Patients), and Market Share (2019-2030) Analysis by Type of Retinoblastoma
    • Non-hereditary
    • Hereditary
  • Global Retinoblastoma Treatment Market Value (US$ Million), Volume (Units/Number of Patients), and Market Share (2019-2030) Analysis by Type of Staging
    • Intraocular
    • Extraocular
  • Global Retinoblastoma Treatment Market Value (US$ Million), Volume (Units/Number of Patients), and Market Share (2019-2030) Analysis by Region
    • North America Retinoblastoma Treatment Market
      • US
      • Canada
    • Latin America Retinoblastoma Treatment Market
      • Brazil
      • Mexico
      • Rest of Latin America
    • Western Europe Retinoblastoma Treatment Market
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe Retinoblastoma Treatment Market
      • Russia
      • Poland
      • Hungary
      • Other CIS Countries
      • Rest of Eastern Europe
    • Asia Pacific Retinoblastoma Treatment Market
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • ASEAN
        • Indonesia
        • Thailand
        • Philippines
        • Vietnam
        • Malaysia
        • Rest of ASEAN
      • Rest of Asia Pacific
    • Middle East & Africa Retinoblastoma Treatment Market
      • GCC
        • Saudi Arabia (KSA)
        • United Arab Emirates (UAE)
        • Rest of the GCC
      • South Africa
      • Nigeria
      • Turkey
      • Rest of the Middle East & Africa

For more information about this report- https://store.rationalstat.com/store/global-retinoblastoma-treatment-market/#tab-ux_global_tab

Key Questions Answered in the Retinoblastoma Treatment Report:

  • What will be the market value of the global retinoblastoma treatment market by 2030?
  • What is the market size of the global retinoblastoma treatment market?
  • What are the market drivers of the global retinoblastoma treatment market?
  • What are the key trends in the global retinoblastoma treatment market?
  • Which is the leading region in the global retinoblastoma treatment market?
  • What are the major companies operating in the global retinoblastoma treatment market?
  • What are the market shares by key segments in the global retinoblastoma treatment market?  

Running a year End discount of 20%-https://store.rationalstat.com/store/global-retinoblastoma-treatment-market/#tab-ux_global_tab

Explore Our Trending Reports

Research Methodology

RationalStat has developed a state-of-the-art research methodology to crunch numbers and provide the best possible real-time insights to clients. We combine a varied range of industry experience, data analytics, and experts’ viewpoint to create a research methodology for market sizing and forecasting.

RationalStat combines a mix of secondary sources as well as primary research to assess the market size and develop a forecast. Key steps involved in accurately deriving the market numbers are:

  • Defining the problem by understanding the type of market and data required by the client.
  • Data gathering and collection through relevant paid databases, publicly available sources, company reports, annual reports, surveys, and interviews.
  • Formulating a hypothesis to create market numbers, forecasts, influencing factors, and their relevance.
  • Evaluating and analyzing the data by referring to data sources utilized and leveraged.
  • Validating, interpreting, and finalizing the data by combining the details gathered from primary and secondary sources with the help of experienced analysts.

Download Key Insights and Market Data - Raise a Query

About RationalStat LLC                    

RationalStat is an end-to-end global market intelligence and consulting company that provides comprehensive market research reports, customized strategy, and consulting studies. The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.

RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, valuations and advisory, financial research, due diligence, procurement and supply chain research, data analytics, and analytical dashboards.

Contact

RationalStat LLC

Kimberly Shaw,

Content and Press Manager

sales@rationalstat.com

US Phone: +1 302 803 5429

UK Phone:  +44 203-287-1245

LinkedIn | FacebookTwitterInstagramPinterest